Literature DB >> 1848493

A correlation study of bone scanning with clinical and laboratory findings in the staging of nonsmall-cell lung cancer.

K Tornyos1, O Garcia, B Karr, R LeBeaud.   

Abstract

Fifty consecutive patients who had a bone scan and a diagnosis of nonsmall-cell lung carcinoma were studied, retrospectively, to determine the usefulness of bone scans in the presurgical workup. Bone scans were interpreted as positive for bone metastases if the scanning abnormality could not be explained by other causes (e.g., trauma or arthritis) or by additional studies (e.g., radiography or CT scanning). Seventeen percent of the patients whose initial clinical and laboratory findings suggested only localized resectable tumor had positive bone scans, changing treatment from surgery to more conservative therapy. Thirty-six percent of patients with no evidence of lung cancer extending to the mediastinum or beyond by CT of the chest and upper abdomen had bone scans indicating bone metastases (positive bone scan). These results suggest that bone scan adds useful information to the presurgical evaluation of patients with nonsmall-cell lung cancer. Clinical findings and/or CT of the chest and upper abdomen are not sensitive or specific enough to exclude bone metastases. Bone scan is recommended before thoracotomy for patients considered for surgery for localized, potentially resectable nonsmall-cell lung cancer.

Entities:  

Mesh:

Year:  1991        PMID: 1848493     DOI: 10.1097/00003072-199102000-00009

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  8 in total

Review 1.  Nuclear medicine.

Authors:  P J Ell
Journal:  Postgrad Med J       Date:  1992-02       Impact factor: 2.401

2.  Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer.

Authors:  Holger Schirrmeister; Coskun Arslandemir; Gerhard Glatting; Regine Mayer-Steinacker; Martin Bommer; Karsten Dreinhöfer; Andreas Buck; Martin Hetzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-28       Impact factor: 9.236

3.  Incidence and consequences of bone metastases in lung cancer patients.

Authors:  Michael Kuchuk; Christina L Addison; Mark Clemons; Iryna Kuchuk; Paul Wheatley-Price
Journal:  J Bone Oncol       Date:  2013-01-17       Impact factor: 4.072

4.  The Impact of Lung Carcinoma Histology on the Frequency of Bone Metastases.

Authors:  Marcelo Bragança Dos Reis Oliveira; Larissa Costa Souza; Ermides Javier Garcia Sampayo; Gustavo Sobral de Carvalho; Fernanda Carvalho de Queiroz Mello; Marcos Eduardo Machado Paschoal
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2019-09-19

5.  Can clinical factors be determinants of bone metastases in non-small cell lung cancer?

Authors:  Ahmet Ursavas; Mehmet Karadag; Esra Uzaslan; Erkan Rodoplu; Ezgi Demirdögen; Basak Burgazlioglu; R Oktay Gozu
Journal:  Ann Thorac Med       Date:  2007-01       Impact factor: 2.219

6.  Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006.

Authors:  Nalini Sathiakumar; Elizabeth Delzell; Michael A Morrisey; Carla Falkson; Mellissa Yong; Victoria Chia; Justin Blackburn; Tarun Arora; Meredith L Kilgore
Journal:  Lung India       Date:  2013-01

7.  Is 99m Tc bone scintigraphy necessary in the preoperative workup for patients with cT1N0 subsolid lung cancer? A prospective multicenter cohort study.

Authors:  Hang Li; Ting Ye; Nan Li; Guozhan Xia; Bin Li; Yang Zhang; Hong Hu; Yihua Sun; Yawei Zhang; Jiaqing Xiang; Dongchun Ma; Yuan Weng; Shilei Liu; Chunyi Jia; Bin Qian; Yajia Gu; Yuan Li; Shaoli Song; Haiquan Chen
Journal:  Thorac Cancer       Date:  2020-11-19       Impact factor: 3.500

8.  When Should ⁹⁹mTc Bone Scintigraphy Be Performed in cT1N0 Non-Small Cell Lung Cancer Patients?

Authors:  Hang Li; Hong Hu; Rui Wang; Yawei Zhang; Jiaqing Xiang; Quan Liu; Wei Shi; Yihua Sun; Haiquan Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.